ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1512

Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis

Andrea Fava1, Avi Rosenberg2, Serena Bagnasco2, Paride Fenaroli2, Jessica Li1, Jose Monroy-Trujillo2, Derek Fine2 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University, Baltimore, 3Johns Hopkins University School of Medicine, Baltimore

Meeting: ACR Convergence 2020

Keywords: Biomarkers, longitudinal studies, Lupus nephritis, Renal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

Session Type: Abstract Session

Session Time: 4:00PM-4:50PM

Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this chronic damage is related to previous inflammatory changes before the biopsy date has not been adequately studied.

Methods: All patients met the revised ACR and/or SLICC SLE classification criteria. We analyzed data from 220 patients with lupus nephritis (543 biopsies) with at least two renal biopsies obtained for clinical purposes. The median time between biopsies was 4 years [IQR 2-9 years]. Patients with pure membranous lupus nephritis on the second biopsy were observed for a median of 7.5 years [IQR 4-12 years]. New onset of end stage renal disease (ESRD) was defined estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73m2, initiation of dialysis, or renal transplantation. Histological chronic changes in pure class V lupus nephritis biopsies were scored by 2 nephropathologists using the NIH chronicity index and averaged when discordant.

Results: Lupus nephritis transitioned to a different class in 136/220 (62%) on repeat biopsy. Pure class V transitioned to proliferative lupus nephritis in 41.5% (Figure 1A). In patients with pure class V on the second biopsy, proliferative lupus nephritis was detected in 52% of the first biopsies (Figure 1B). Surprisingly, the NIH chronicity index did not differ between class V vs. class III and IV (p=0.5) and it was numerically higher (Figure 2A). The chronicity index in repeat biopsies was higher than in first biopsies. In particular, patients with proliferative lupus nephritis in the first biopsy who transitioned to class V had numerically worse chronicity index than those with class V in the first biopsy (5 [3.75-6.5] vs. 3 [1.5-5], p=0.13) (Figure 2B). New onset ESRD was observed in 5/52 (9.6%) patients with pure class V. All 5 patients (100%) had proliferative lupus nephritis in the first biopsy (p=0.04) (Figure 3).

Conclusion: Lupus nephritis is a dynamic disease, with the separation of membranous and proliferative an artificial division based on a kidney biopsy. Non-proliferative lupus nephritis may be preceded by proliferative disease which is associated with risk of ESRD. Chronic damage, a known negative prognostic factor, is commonly observed in pure membranous nephritis and it is associated with previous proliferative disease. The management of membranous lupus nephritis should involve immunosuppression to address the high frequency of proliferative nephritis on repeat (or preceding) biopsies to proliferative disease and quantification of chronic damage should be pursued in all classes.

Figure 1. Transition across lupus nephritis classes in repeat renal biopsies. Change of ISN class from first (bx1) to second (bx2) biopsy according the class of the first (A) or the second biopsy (B). Numbers in the circles indicate the number of biopsies. The size of the circle indicates the proportion of biopsies within each ISN class for each plot.

Figure 2. Chronic renal damage is observed in pure class V lupus nephritis and is associated with previous episodes of proliferative disease. (A) NIH chronicity index in the nephritis cohort. There was no statistically significant difference across groups. (B) NIH chronicity index in pure class V renal biopsies according to the class of the preceding renal biopsies.

Figure 3. Renal survival of patients with pure class V lupus nephritis in a repeat renal biopsy according the histological class of the initial biopsy. P value was calculated using the log rank test.


Disclosure: A. Fava, None; A. Rosenberg, None; S. Bagnasco, None; P. Fenaroli, None; J. Li, None; J. Monroy-Trujillo, None; D. Fine, GSK, 5; M. Petri, AbbVie, 5, Amgen, 5, AstraZeneca, 2, 5, BMS, 5, Decision Resources, 5, GSK, 2, 5, INOVA, 5, IQVIA, 5, Janssen, 5, Eli Lilly, 2, 5, Merck EMD Serono, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5, Exagen, 2.

To cite this abstract in AMA style:

Fava A, Rosenberg A, Bagnasco S, Fenaroli P, Li J, Monroy-Trujillo J, Fine D, Petri M. Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/trajectory-analysis-of-repeat-renal-biopsies-identified-previous-endocapillary-proliferation-as-predictor-of-damage-and-end-stage-renal-disease-in-pure-membranous-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trajectory-analysis-of-repeat-renal-biopsies-identified-previous-endocapillary-proliferation-as-predictor-of-damage-and-end-stage-renal-disease-in-pure-membranous-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology